MT2004-24: AutoPBSCT inLymphoma
1UNIVERSITYOFMINNESOTABONEMARROWTRANSPLANTATIONPROGRAM
AutologousPeripheralBloodStemCell TransplantforPatientswithLymphoma
CPRC#2005LS048
MT2004-24
StudyCommittee:
VeronikaBachanova,MD(Chair)
LindaBurns,MD
DanielWeisdorf,MD
JeffreyMiller,MD
KathrynDusenbery,MD
DavidMcKenna,MD
Jo-AnneYoung,MD
QingCao,MS(biostatistician)
VersionDate: January16,2014
Confidential
MT2004-24: AutoPBSCT inLymphoma
2TABLE OF CONTENTS
1 OBJECTIVES....................................................................................................5
2 BACKGROUND AND RATIONALE .......................................................................5
3 ELIGIBILITY AND EXCLUSION CRITERIA...........................................................7
4 SUBJECT REGISTRATION...............................................................................11
5 TREATMENT PLAN .........................................................................................11
6 REQUIRED OBSERVATIONS ( APPENDIX V) ....................................................20
7 ENDPOINTS...................................................................................................22
8 TRANSPLANT RELATED TOXICITIES AND COMPLICATIONS .............................22
9 ADVERSE EVENT REPORTING ........................................................................28
10 DATA AND SAFETY MONITORING...................................................................30
11 EXPERIMENTAL DESIGN AND STATISTICAL CONSIDERATIONS........................30
12 ESTIMATION OF CELLS..................................................................................33
13 ADMINISTRATIVE PROCEDURES ....................................................................34
14 REFERENCES.................................................................................................34
MT2004-24: AutoPBSCT inLymphoma
3RevisionHistory
date Revision details Consentchange/
versiondate
08/23/05 original
1/30/07 1. Clarificationofminimum celldoserequiredfor individuals requiring
bonemarrowharvest.
2. AdditionofRituximabtherapypost-transplantforCD20+NHL
3. AdditionofriskofJCvirus with progressivemultifocal
leukoencephalopathydue toRituximab.
2/15/2007 Revisedeligibility(p.7) andcellcollectionsections(p.11)toallowfor
identicaltwindonor
8/10/2007 Revisedmobilizationtoallowfor patientswhohave alreadyfailed
(R)ICEtouseanalternateconditioning regimen.
7/15/2009 Dr.Bachanovareplaces DrTomblynas PI
4/1/2010 Standardized the cytoxan dosing in obesity (sections 5.3.1 and 12.2)
9/23/2010 Changedupper ageeligibilityto75
DeletedTrec blooddraws andanalysis
05/17/2013 AddBEAM as analternativepreparativeregimenforpatientsunableto
receivedadditionalradiationtherapyand/orhighdose
cyclophosphamide
updateregistration, eventreportingandtoxicitysectionsYes
8/5/2013 Fixedcut&pasteerrorintheBEAMappendix –toxicitychartfor
BCNUYes
1/16/2014 Fixedadditionalcut&paste errorintheBEAMappendix –toxicity
chartforBCNU;correctBCNU (carmustine) infusiontime–over 2
hours, not1hourYes
MT2004-24: AutoPBSCT inLymphoma
4SCHEMA
NHL,including
HIVinfected
Mobilizationbyeither: Peripheral Transplantusing:
1) anotherprotocol,if eligible StemCell CTXplusTBI(NHL) Post-transplantF/U&
2) G-CSFalone Collection CTX,BCNU,VP-16(HLor immunereconstitution
3) ICE+/-Rituximab (NHL with priorRT) studies
4) Alternativeconditioning if BEAM
ineligible for1,2,or3.
Hodgkin’s
Lymphoma
OtherrelatedActivities: For calculationofPBSC harvest
Recordeach dayof leukapheresis:
thepbCD34/µLpriortocollection,
thetotalnumber ofCD34+cells harvested,
thevolumeofapheresis plus thepatient’sheightandweight
Evaluationsforimmunereconstitution
QuantitativeImmunoglobulinsandCD4andCD 8–priortomobilization, day+100 andthenq3mon for1yr
For HIV-positivepatients,CD4andCD8analysisat d+28andd+60as well.R
E
G
I
S
T
E
R
MT2004-24: AutoPBSCT inLymphoma
51.0 OBJECTIVES
Autologoushematopoieticstemcelltransplant(HSCT)isappropriatecarefor
manypatientswithHodgkin(HL)andnon-HodgkinLymphomas(NHL).
1.1 PrimaryObjective
1.1.1Todeterminethediseasefreesurvivalandoverallsurvivalafter
autologousHSCTforNHLandHL
1.1.2ToverifythesafetyandefficacyofautologousPBSCHSCTin
patientswithHIVdiseaseandrelapsedlymphoma
1.2 SecondaryObjectives
1.2.1ToevaluateimmunereconstitutioninHIVpositivepatients
undergoingautologousHSCTandcomparetoimmune
reconstitutioninHIVnegativepatients
1.2.2Topredicttheadequacyof PBSCharvestpriortoflowanalysisof
aPBSC yield(seeSection12.2)
1.2.3Todeterminethetimetoengraftmentforneutrophilsandplatelets
2.0 BACKGROUNDANDRATIONALE
Theroleofhigh-dosechemotherapyandHSCTinthetreatmentof relapsed
lymphomaiswellestablished1,2. Sincethattime,continuedimprovementsin
survival,supportivemanagementandtransplanttechniqueshavedeveloped.
Consequently,itisimportanttocontinuetoscientificallystudyissuesrelatedto
autologousHSCTforpatientswithlymphomas.
Peripheralbloodstemcells(PBSC)arenowusedalmostexclusivelyasthesource
ofhematopoieticreconstitutionforpatientstreatedwithautologousHSCTforboth
NHLandHL. TheuseofPBSCinsteadof bonemarrowhasresultedinmorerapid
hematopoieticengraftment3,4. AlimitationtoautologousHSCTissufficientharvest
ofthe2x106CD34+cells/kgminimumthresholdconsiderednecessaryfor
satisfactoryengraftment5. Optimalestimationofharvest yieldpriortotheactual
collectionisdifficult. Surrogatemarkershavebeenstudiedincludingthewhite
bloodcellandplateletcountsonthedayofleukapheresisandthenumbersof
MT2004-24: AutoPBSCT inLymphoma
6circulatingCD34+cells6,7. Themostusefulmarkertodateistheperipheralblood
CD34+cells/µL8.
Evenwiththissurrogatemarker,somepatientsdonotmobilizeadequatenumbers
ofPBSCtoproceedwithtransplantandalternativemeansofhematopoieticstem
cellharvestmustbeundertakenoralternativetherapysought. Inapreviousstudy
of175patientswithlymphomaundergoingPBSCharvestandautologousHSCTat
theUniversityof Minnesota,41(23%)hadinadequatePBSCcollectionsdefinedas
totalcollectionoflessthan2x106CD34+/kg. Twenty-eightof thesepatientswent
ontobonemarrowharvest9. Withareliablemeanstopredicttheharvest yield,
thesepatientsmayhavebeensparedtreatmentdelayandthemorbidityand
expenseof additionalleukaphereses. Insteadtheremayhavebeenconsideration
forinitialbonemarrowharvestorallogeneictransplant.
Thekineticsandyieldofmobilizationaredependentuponthevolumeof apheresis
andthecollectionefficiencyaswellastheperipheralbloodCD34+cells/µL10,11.
Consequently,evenwithsufficientcirculatingperipheralbloodCD34+cells,patients
stillmaynotharvestwellduetopoorcollectionefficiency. Itwouldbevaluableto
haveameanstoestimatestemcellyieldaccuratelytodetermineiftheminimum
thresholdof PBSCcouldbeobtainedwithfurthercollectionproceduresratherthan
abortingthewholeprocess.
ApreviouslypublishedretrospectiveanalysisconductedbyGidron et alfoundthat,
eveninthesettingofalowperipheralbloodCD34+cellcount,adequatePBSC
couldbeharvestedifthecollectionefficiencyandnumbersof harvestswas
adequate12. Theyretrospectivelyreviewed485PBSCharvestswherethe
peripheralbloodCD34+countwasknown. In104harvests,thecirculating
peripheralbloodCD34+cellswere<5/µL,acut-offthoughtindicativeof poor
collection. However,over60%oftheseharvestscontainedmorethan0.3x106
CD34/kgsuchthatapersonundergoingleukapheresisfor6-7dayswouldobtain
anadequategrafttomoveforwardtotransplant. Usingthisdata,theydetermined
anequationusefultoestimatethePBSCharvestbasedoncollectionefficiency,
volumeofleukapheresis,theperipheralbloodCD34+cellcount/µL,andthe
patient’sidealbodyweight(IBW). Thisstudywillattempttovalidatethatformulain
aprospectivestudy.Thatvalidationwillallowforbetterestimatesofstemcell
harvestforpatientsplannedforautologousHSCTforthemanagementof
lymphoma.
Lymphomaisafrequentcomplicationof HIVdisease. Withtheadventofhighly
activeanti-retroviraltherapy(HAART),transplantisbeinginvestigatedforpatients
withHIVandlymphoma13-15. Asmallcaseseries(n=9)fromtheCityofHope
demonstratedadequateengraftmentsimilartonon-HIVinfectedpatients16. All
patientshadeitherNHLorHLandwereonHAARTtherapy. Patientswere
conditionedwithcyclophosphamide,BCNU,andetoposide(CBV). Themedian
timetoneutrophilandplateletengraftmentwas11and10days,respectively.
Furthermore,despiteatransientdecreaseinCD4+countstoanadirof138/µLat
MT2004-24: AutoPBSCT inLymphoma
7twomonthspost-transplant,themajorityrecoveredpre-transplantCD4+levelsata
medianof14monthspost-transplant. Infectionsduringtheneutropenicperiod
includedbacteremias, Clostridium difficile colitis,andanepisodeofculturenegative
sepsis. Threepatientssubsequentelydevelopedopportunisticinfectionsincluding
zoster,cytomegalovirusviremia,and Pneumocystis carinii pneumoniainapatient
whostoppedhisprophylacticantimicrobials. Reandcolleaguespublishedanother
smallseries(n=16)withsimilarresults17. Inbothseries,therewerenodeathsdue
totreatmentor opportunisticinfection. Furthermore,intheseriesfromKrishan et
al,sevenoftheninepatientswereinremissionatamedianof19monthsafter
transplant.Whiletheliteraturesupportsthesafetyandbenefitoftransplantation,
theimpactonimmunereconstitutioninHIVpatientsisunclear.
3.0ELIGIBILITY ANDEXCLUSIONCRITERIA
3.1 Age: Allpatientsmustbelessthan75yearsofageatthetimeof enrollment
inthestudy.
3.2 Karnofskyperformancestatus: >80%(>60%ifpoorperformancestatusis
relatedtolymphoma)[AppendixI]
3.3 Lifeexpectancy: Greaterthan8weeks.
3.4Noevidenceof seriousorgandysfunctionthatisnotattributabletotumor
including:
3.4.1 Renal : Creatinine ≤ 2.0 mg/dl or creatinine clearance > 50 ml/min. 
3.4.2 Hepatic :Nohistoryofseverepriororongoingchronicliverdisease.
Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase <5x 
upperlimitofnormal.
3.4.3 Cardiac :Patientsmustbefreeof symptomsofuncontrolledcardiac
diseaseincludingunstableangina,decompensatedcongestive
heartfailure,orarrhythmia.Theejectionfractionbygatedcardiac
bloodflowscan(MUGA)mustbe>45%.
3.4.4 Pulmonary :Patientsmusthavenosignificantobstructiveairways
disease(FEV 1 must be ≥ 50%) and must have acceptable diffusion 
capacity(correctedDLCO>50%of predicted).
3.4.5 Hematologic: Patientsmusthave(1)hemoglobin>8gm/dL
withouttransfusionandofferythropoietinfor14daysorAranesp
for21days;(2)WBC>2.5x109/LwithanANC>1.5x109/LoffG-
CSForGM-CSFfor10daysorNeulastafor21days;(3)Platelets
>100x109/Lwithouttransfusion;(4)Bonemarrowcellularityof >
20%with<10%involvementwithtumor
3.4.6 Centralnervoussystem: Patientswithahistoryof CNSinvolvement
bylymphomaorwithrelapsedprimaryCNSlymphomawillbe
MT2004-24: AutoPBSCT inLymphoma
8eligible. PatientswithactiveCNSdiseaseareeligibleiftheyhave
completedastandardtreatmentforCNSlymphomaandhaveno
evidenceofprogressiveCNSdiseaseatthetimeofenrollment.
3.4.7 Infection: Patientswithseriousuncontrolledinfectionsatthetime
of transplantwillbeexcluded
3.5Patientsmustbeatleast4weeksfrompreviouschemotherapy;6weeksfrom
nitrosoureas.
3.6 HepatitisB: Patientswhoarecarriersof HepatitisBwillbeincludedinthis
study. Thesepatientsarenoteligible toreceiverituximabasacomponentof
theirchemotherapymobilization18.
3.7 HIVdisease
PatientswithHIVdiseaseareeligibleforthisstudyprovidedthat:
3.7.1 Patientswillbeseenintheinfectiousdisease(ID)/HIVclinicpriorto
enrollmentonstudyforthepurposeof determiningeligibilityandfor
localcoordinationofHIVcareduringtheperi-transplantperiod.
3.7.2 Mustbeonamaximallyactiveanti-HIVregimentocontroldisease
asdeterminedappropriatebytheID/HIVphysicians. Forthe
majorityof patients,thiswillbeahighlyactiveanti-retroviral
therapy(HAART)-typetherapyincludingaproteaseinhibitor.
3.7.3 CD4+ ≥ 50/µL 
3.7.4 HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 
weeksapart. Themostrecentlevelmustbewithinonemonthof
enrollment.
3.8 Non-Hodgkin’slymphoma(NHL)
Patientswithchemo-sensitivehistologicallyconfirmedNHLwillbeeligiblefor
thistreatmentprotocolcontingentonhistologicsubclassification.
NHLpatientswithresistantorrefractorylymphoma(noPRfollowingupto
threecyclesof combinationchemotherapy)willbeineligible fortransplantin
thistrial.
3.8.1 PrecursorB-cellorPrecursorT-cellNHL
3.8.1.1 Lymphoblasticlymphoma
Allpatientswillbeeligibleinsecondorgreatercomplete
remission(CR)orfirstorsubsequentpartialremission(PR).
Patientswithanyhigh-riskfeatureswillbeeligibleinfirst
completeremission
Highriskfeaturesinclude:
StageIV;
MT2004-24: AutoPBSCT inLymphoma
9LDH>2xnormal;
 ≥ 2 extranodal sites. 
3.8.2 MatureB-cellLymphomas
3.8.2.1 Smalllymphocyticlymphoma(SLL)orChronicLymphocytic
Leukemia(CLL)
 Patients will be eligible in ≥ CR1 with molecularly 
negativedisease
PatientsinCRwithmolecularlypositivediseaseorin
PRwillbeexcludedfromautologoustransplant.
3.8.2.2 FollicularLymphoma
 Patients will be eligible in ≥ first CR/PR (if treatment is 
delayeduntilclinicallyrequired).
Patientswhoaretreatedatdiagnosis(withoutclinical
symptomsnecessitatingtreatment,suchasB symptoms,
bulkydisease,marroworotherorgancompromise)willbe
eligible in ≥ second CR/PR. 
3.8.2.3 DiffuseLargeB-cellLymphoma
 All patients will be eligible in ≥ CR2 or ≥ PR1.  
 Patients with a high intermediate or high IPI (≥ 2 for 
age-adjusted IPI or ≥3 for IPI) at diagnosis will be 
eligibleinfirstCR.
3.8.2.4 MantleCellLymphoma
AllpatientswillbeeligibleinfirstorgreaterCRorPR.
3.8.2.5 Burkitt’s/Burkitt’slike
Allpatientsexceptlocalizedlymphomawillbeeligible
anytimeafterinitialtherapy(afterachievementoffirst
completeremission),orinpartialremissioniftheyfail
toachieveCR.
Patientswithlocalized(stageIorZieglerstageA) will
beeligibleonlyif theyfailtoachieveCR1or after
relapse
3.8.3 MatureT-celllymphoma
T-celllymphomasincludingPrimaryT-cellnot
otherwisespecified,angioimmunoblastic,andALK-
MT2004-24: AutoPBSCT inLymphoma
10positiveanaplasticlargecell,willbeeligibleafter
initialtherapy, whether ornotCRisachieved.
Mycosisfungoides/Sezarysyndromewillbeeligiblein
≥CR2/PR2 
3.9 Hodgkin'slymphoma(HL)
PatientswithhistologicallyprovenHLwillbeeligiblefortransplantationafter
failingpriortherapy.
Patientswithresistantdisease(initialoratrelapse): thosewhofailto
achieveanobjectivepartialresponsetothreecyclesofcombinationnon-
crossresistantchemotherapywillbeineligible fortransplantinthistrial.
3.9.1 ForstageI/IIpatientstreatedwithprimaryradiation,theymust
havefailed(noCR or progressionafterCR)atleastonesalvage
combinationchemotherapytreatmentregimen.
3.9.2 Foradvanced(stageIII/IV)Hodgkin'sdisease,patientsmusthave
failedanadriamycincontainingregimen(ABVD)oranalternative
non-crossresistantregimen(egMOPP).
3.9.3 Patientswithanyhigh-riskfeatureswillalsobeeligible,including
thosewho:
Failtoachievecompleteremissionwithinitialcombination
chemotherapy
Patientswithbulkydiseaseafterinitialtherapy
(chemotherapyorradiation)definedasresidualmediastinal
mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied 
byotherfeaturesofpersistingdisease(e.g.,GalliumorPET
scanpositive;highLDH;enlargingonserialx-raysorbiopsy
positive)willbeeligible. Ifpossible,persistent disease
shouldbeprovenbybiopsy.
3.9.4 PatientsshouldreceivechemotherapytoattempttoachieveCRor
minimaldiseasestateforallpatientspre-transplantation.Theuseof
uptothreecyclesofnon-crossresistantcombinationchemotherapy
isadvised.
3.9.5 Residualareasoflimiteddiseaseshouldreceiveradiotherapy
followingandnotpriortotransplantation(SeeSection5.4).
3.10AllresponsesaretobedeterminedusingtheResponseCriteriaforNon-
Hodgkin’sLymphoma19(AppendixII)andwillincludePET/CTpriortoHCT.
3.11Allparticipatingpatientsmustexerciseinformedvoluntaryconsentandsigna
consentformapprovedbytheUniversityofMinnesotaCommitteeonthe
UseofHumanSubjectsinResearch.
MT2004-24: AutoPBSCT inLymphoma
113.12Patientsmaybetransplantedunderthisprotocolusingasyngeneic
(identical)twindonor.
3.13Exclusions
3.13.1 Patientseligibleforanyhigherprioritytransplantprotocols
3.13.2 Womenwhoarepregnantorbreastfeeding
3.13.3 Patientswithchemotherapyresistantdisease
4.0SUBJECTREGISTRATION
PatientswillberegisteredtothisstudyinOnCoreatthetimeofconsentsigning.
5.0TREATMENTPLAN
5.1 PeripheralBloodStemCell(PBSC)Mobilization
AllpatientswillhavePBSCcollectedbyleukapheresis. Patientsmaybe
eligibleandenrolledonother higher priorityPBSCmobilizationstudies.
Patientsnotrequiringfurtherdiseasereduction(i.e.inCRorverygoodPR
aftersalvagechemotherapy)canbemobilizedwithG-CSF aloneat adose
of 10µg/kg/daysub-cutaneously(seeAppendixIII)9.
CRorCRu: definitionperAppendixII
VerygoodPR: definedasminimalresidualdiseasewithallnodalsites
≤2 cm and no morphologic bone marrow involvement 
PatientswithstageIVdiseaseatthetimeofdiagnosisormorethan1year
fromtimeof diagnosistoplannedharvestshouldbeconsideredfor
chemotherapyprimingifnoteligibleforalternativePBSCmobilization
studies9.
Ifpatientshaveprogressedthroughthe(R)ICEregimen,thenanalternative
conditioningregimenwillbeusedatthediscretionofthetreatingphysician.
OnesuggestionistouseCyclophosphamide4000mg/m2asperprotocol
MT2003-13. R-DHAPandGemcitabinebasedregimen(Gemcitabine,
Vinorelbine,Dexamethasone)arealsopermitted.Rituximab375mg/m2may
beco-administeredifthepatienthasaCD20+lymphoma.
MT2004-24: AutoPBSCT inLymphoma
125.1.1 MobilizationwithG-CSFalone
G-CSF10µg/kg/daysubcutaneouslyqdayeachmorning(priortoharvestondays
ofapheresis)untilcompletionof harvest
Leukapheresis willbeginonday5of G-CSF administration
IfpatientsdonotadequatelymobilizewithG-CSFalone,theywillthenreceive
chemo-mobilization(see5.1.2)
5.1.2 Chemo-mobilizationusingICE±Rituximab(R-ICE)
Patientsrequiringfurtherdiseasereduction(i.e.PRaftersalvagechemotherapy)
orotherseligiblewillreceivechemo-mobilizationusingIfosfamide,Carboplatin,
andEtoposide(ICE)±Rituximab(R-ICE). Thismaybeadministeredeitherasan
inpatientoroutpatient.
PatientswithCD20+NHLorlymphocytepredominantHLwillhaveRituximab
includedintheirmobilizationchemotherapy.PatientswhoarecarriersofHepatitis
BarenoteligibletoreceiveRituximabregardlessoftheirdiseasetype.
Chemotherapyformobilizationwillbeadministeredasfollows:
Day Drug Administration
1 Rituximab
(CD20+NHLor
lymphocytepredominant
HLpts.only)375mg/m2onday1infusedover6-8 hours. Infusionshould start
at50mg/hr andincreaseby50mg/hr every30 minutes as
toleratedtoamaximalinfusionrateof400mg/hr
Premedicationwith acetaminophen650mgandbenadryl50mg
orally. Hydrocortisone50mgIVmaybeadministeredif
necessaryforinfusionreactions.
Day2Ifosfamide 1665mg/m2/dayIVover2hours
MESNA 1665mg/m2/dayIVover2hoursgiven concomitantlywith
Ifosfamide
Etoposide(VP-16) 100mg/m2/dayIVover30minutes afterIfosfamide
Carboplatin AUC 5(max dose350mg/m2; see Appendix III)IVover 1hour
afterEtoposide
Day3, 4Ifosfamide 1665mg/m2/dayIVover2hours
MESNA 1665mg/m2/dayIVover2hoursgiven concomitantlywith
Ifosfamide
Etoposide(VP-16) 100mg/m2/dayIVover30minutes afterIfosfamide
MT2004-24: AutoPBSCT inLymphoma
13Start
Day5G-CSF 10µg/kg/daySQ(dosedper appendixIII)untilcompletionof
leukapheresis
Ifosfamidewillbedosedbasedonactualbodyweight(ABW)
unlessthepatientis20%ormoreofidealbodyweight(IBW)[See
section12.2forIBW formula]. Ifmorethan20%of idealbody
weight,anadjustedidealbodyweight(AIBW)willbeusedfor
dosing. Thisiscalculatedas:
AIBW=IBW+1/3(ABW-IBW)
Leukapheresis will begin the first day after the ANC ≥ 1.0 x 109/L.
Thiswilllikelybebetweenday+12andday+15aftertheinitiation
of chemotherapy.
5.1.3 SupportiveCareduringChemotherapymobilization
5.1.3.1 IVHydration: Allpatientswillbegivenaminimumof1
LiterofNormalSalinedaily(days1–4)during
chemotherapymobilization. AdditionalIVhydrationcan
begivenatthephysician’sdiscretion.
5.1.3.2 Prophylacticantiemeticswillbeadministeredasfollows:
day2(priortoIfosfamide,VP-16,andCarboplatin):
Ondansetron32mgIVanddexamethasone20mgIVplus
lorazepam1mgpo/IV30minutesbeforechemotherapy.
days3and4: Ondansetron8mgoraldissolvingtablet
(ODT)every8hoursanddexamethasone10mgIV30
minutesbeforechemotherapy.Lorazepamand
prochlorperazinecanbegivenIV/POevery6hoursas
needed.
5.1.3.3 Forpatientswithuricacid>5.0mg/dlonthefirstdayof
chemotherapy,addallopurinol300mg/dor 150mg/M2/d
pofor7daysorlonger ifhyperuricemia(>10mg/dl)
persists.
5.1.3.4 Beginningday5ofmobilization,patientswillbe
monitoredclosely(atleastq48hbutdailyifmedically
necessary)withcarefulobservationforfever,infection,or
anemiaorthrombocytopenianeedingtransfusion
support.
5.1.3.5 Allbloodproductsadministeredmustbeirradiatedbefore
infusionandif thepatientisCMVseronegative,mustbe
CMV-safe(CMV-seronegativeorleukocytedepletedby
filtration).
5.1.3.6 Antibioticprophylaxisstartingonthefirstdayof
chemotherapywillincludeLevofloxacin500mgpodaily
andFluconazole200mgpodaily.Acyclovir400mgpo
TIDshouldbegiventoifpatient’sareseropositivefor
MT2004-24: AutoPBSCT inLymphoma
14HSV.  Antibiotic prophylaxis will continue until the ANC ≥ 
1.0x109/L
5.1.3.7 Neutropenicfeverorsignsofinfectionshouldbe
investigatedpromptlyandtreatedempiricallywithbroad
spectrumIVantibiotics.
5.1.3.8 CBCdifferentialandplateletsshallbemonitoredatleast
q48hours
5.2 PeripheralBloodStemCellCollection
5.2.1Patientsmusthavesatisfactoryvenousaccessusingappropriate
largeborevascularaccesscatheters suitableforrepeated
leukapheresis. (Hickman/Leonardtypesarenotacceptable;
QuintonorDavoldoublelumensubclavian13.5Frenchdialysis
cathetersarerequired.)
5.2.2 Collection starts on the first day after the ANC ≥ 1.0 x 109/Lafter
R-ICEoronday5of G-CSFif notchemo-mobilized
AperipheralbloodCD34+(pbCD34)cellcount/µLwillbedrawnin
clinicdailypriortoapheresisstartingthefirstdayofleukapheresis
andcontinuingthroughtheentireperiodof leukapheresis
5.2.3Peripheralbloodstemcellcollectionproceedsforaminimumof3
daysregardlessofthemeasuredpre-collectionpbCD34/µLunless
thegoal(5x106CD34+/kg)collectionismet(seeSection5.2.4).
However,if patientsdonotcollectaminimumof 0.1x106CD34+
cells/kgonthefirstdayofapheresisor atotalof 0.3x106CD34+
cells/kgbythecompletionof day2of apheresis,theleukapheresis
procedurewillbeabortedandalternativemeansofhematopoietic
stemcellcollectionwillbedeterminedasdefinedbelow
DecisionsregardingcontinuedPBSCcollectionbeyond3days
shouldbebasedonthefollowing:
5.2.3.1 IfthepbCD34/µLiscontinuingtoincreaseandthegoalof
5x106CD34+cells/kghasnotbeenreached,thenfurther
collectionsshouldproceed. Thisincreaseshouldbeby
atleast1/µL/daytocontinueaslongastheminimum
pbCD34/µL is ≥5.   
Forexample,if onday2,thepbCD34/µLis5andonday
3,thepbCD34/µLis6,then,if necessary,thecollection
couldproceedtoday4. IfthepbCD34/µLonday4has
declinedorreachedaplateau,afifthdayofharvest
wouldnot bedone. However,if thepbCD34/µLis7,then
apheresiscouldcontinueif necessary.
SeeSection12.1forformulatocalculatepbCD34/µL
MT2004-24: AutoPBSCT inLymphoma
155.2.3.2 IfthepatientwasmobilizedwithG-CSFalone,then
growthfactorshouldbestoppedandthepatientshould
proceedtochemo-mobilization(see5.2.4)
5.2.3.3 Ifthepatientwaschemo-mobilized,thenarecovery
periodof 1–2weeksshouldbegivenanddecisionmade
foralternativemeansofharvest(see5.2.4)
5.2.4Targets
Goalcollection: 5x106CD34/kgactualbodyweight
Minimalperipheralbloodcollectiontoproceedtotransplant: 2x
106CD34/kgactualbodyweight.
Minimumcollectiontoproceedtotransplantifpatientrequiresa
bonemarrowharvest(seebelow): 1x106CD34/kgactualbody
weight.
If<2x106CD34/kgactualbodyweightarecollected,alternative
harvestingprocedureafterANC>1.5x109/LandPlt>100x109/L
off G-CSFwillbeperformed
IfpatienthadpreviouslyundergoneG-CSFmobilization,
thenchemotherapymobilizationusingICE±Rituximabper
5.1.2
Ifpatienthadpreviouslyundergonechemotherapy
mobilization then, if bone marrow biopsy is ≥20% cellular 
andwithoutmorphologicevidenceof lymphoma,patients
willbegivenGM-CSFat10µg/kg/dayfor5days. Onday5,
patientswillundergoa1.5Lbonemarrowharvest. For
patientsrequiringabonemarrowharvest,theminimum
CD34+cell/kgdoseis1x106CD34/kgactualbodyweight.
Ifpatientsdonotachievetheminimalcollectiongoalwith
combinationof growthfactorandchemotherapy
mobilizationanddonotmeetthebonemarrowbiopsy
criteriatomoveforwardwithbonemarrowharvest,theywill
beremovedfromthetransplant portionofthestudy. Data
collectedforharvestwillbeusedintheevaluationof
appropriatesecondaryendpoints.
5.2.5 Syngeneic(identical)twindonorswillbemobilizedaccordingto
standardclinicalpractice(asoutlinedinallogeneicprotocol
MT2001-02)
MT2004-24: AutoPBSCT inLymphoma
165.3 Transplant Admission
5.3.1 Non-Hodgkin’slymphomaincludingirradiation
Forpatientswhohavehadgreaterthanthefollowingpre-
transplantradiotherapylimits,treatment willbepersection5.3.2:
i) >1000cGytowholelung,kidney,orabdominalbath.
ii) >3000cGytospinalcord,myocardium,mediastinum,lumbar
periaorticlymphnodes.
iii)>3600cGytowholebrain.
Day Procedure
Day-8 Admission
Day-7, -6 Cyclophosphamide 60mg/kgi.v.overtwohoursdailyx2days(total120mg/kg).
Day-5 Rest
Day-4, -3,-2,-1 Totalbodyirradiation(TBI)165cGyb.i.d.x4days(total1320cGy).
Day0 ReinfuseallpreviouslycollectedPBSC.
Day+5 BeginG-CSF5µg/kg/daySQ roundedtothenearestvialsize.
Continue G-CSF until ANC > 1500/μl x 3 consecutive days. 
IfANC falls<1000/µL, restartG-CSF.
CyclophosphamidedosingiscalculatedbasedonABW (actual
weight) unlessABW is>150%of IBW (IdealBodyWeight).In
thiscasethedoseshouldbecomputedusingadjustedbody
weight.
Idealbodyweightiscalculatedusing:
50kg+[2.3kgx(heightininches-60)]formen
45.5kg+[2.3kgx(heightininches-60)]forwomen
Adjustedbodyweight=IBW +0.5(ABW -IBW)
TBIwillbegivenby6, 18,or24MVx-raybeamsthroughright
andleftlateralfieldsprescribedattheumbilicusatmidplane.
Aluminumcompensatorswillbeusedasnecessarytodelivera
uniformdosewithin±10%oftheprescribeddose. Abeam
spoiler willbeusedtopreventskinsparing. Thedoseratewill
be10-19cGy/min. Totaldosewillbe1320cGyadministeredin8
MT2004-24: AutoPBSCT inLymphoma
17fractionsover 4days.Theintervalbetweenfractionsshouldbeat
least6hours.
5.3.2 Non-Hodgkin’sLymphoma.Radiation-freeand
Cyclophosphamide-freeregimen
ForpatientswithNHL
ineligibletoreceivetotalbodyirradiationbecauseofprior
radiation(asabove)tocentralnervoussystem,lungs,or
heartinexcessivedoses,or
patientswhoarenotcandidatesforhighdose
cyclophosphamideduetoexcessiveriskof toxicity,the
followingconditioningregimenwillbeused.
Treatment willbeadministeredpercurrentinstitutionalguidelines.
Day Procedure
Day-7 Admission
Day-6 BCNU 300mg/m2IVover2hours
Day-5 Etoposide 100 mg/m2IVover 2hoursBID
AraC 100mg/m2IVover1hour BID
Day-4 Etoposide 100 mg/m2IVover 2hoursBID
AraC 100mg/m2IVover1hour BID
Day-3 Etoposide 100 mg/m2IVover 2hoursBID
AraC 100mg/m2IVover1hour BID
Day-2 Etoposide 100 mg/m2IVover 2hoursBID
AraC 100mg/m2IVover1hour BID
Day-1 Melphalan140mg/m2IVover1hour
Day0 Re-infuseallpreviouslycollectedPBSC
Day+5 BeginG-CSF5µg/kg/daySQ roundedtothenearestvialsize.
Continue G-CSF until ANC > 1500/μl x 3 consecutive days. 
IfANC falls<1000/µL, restartG-CSF.
BEAMconditioningregimencanbeusedforHLpatientsonlyiftheyareineligible
forCBV(detailedbelow).
MT2004-24: AutoPBSCT inLymphoma
185.1.3 Hodgkin’sLymphomaWithoutIrradiation
ForpatientswithHLthefollowingconditioningregimenwillbeused.
Day Procedure
Day-7 Admission
Day-6, -5,-4,-3 Cyclophosphamide1.5 gm/M2over 2hours at10a.m.dailyx4days.(Totaldose
ofcyclophosphamide6gm/M2)
Day-6 BCNU (carmustine) 300mg/M2over2 hours,9am.
Day-6, -5,-4 Etoposide(VP-16) 150mg/M2intravenouslyover 4hoursevery12hours starting
at6AMand6PM,for6totaldoses.(Totaldose:900mg/M2)
Day-2, -1 Rest
Day0 ReinfuseallpreviouslycollectedPBSC
Day+5 BeginG-CSF5µg/kg/daySQ roundedtothe nearestvialsize.
Continue G-CSF until ANC > 1500/μl x 3 consecutive days. 
IfANC falls <1000/µL,restartG-CSF.
Cyclophosphamidewillbedosedbasedonactualbodyweight
(ABW)unlessthepatientis20%ormoreofidealbodyweight
(IBW)[Seesection12.2forIBW formula]. Ifmorethan20%of
idealbodyweight,anadjustedidealbodyweight(AIBW)willbe
usedfordosing. Thisiscalculatedas:
AIBW=IBW+1/3(ABW-IBW)
5.1.4 SupportiveCare
5.1.4.1 Allpatientswithuricacid>5.0mg/dlwillreceive
allopurinol(300mg/dor150mg/M2/dpo)beginningon
admissionandcontinuingtoDay-1unless
hyperuricemia(>10mg/dl)persists. Allopurinolmaybe
stopped when uric acid ≤ 5mg/dL. 
5.1.4.2 Vigorousintravenoushydration(2000-3000ml/m2/day)
shouldbegivenfrom4hoursbeforethefirst
cyclophosphamidedoseuntil24hourspastthesecond
dose.Adequatediureticsshouldbegivenandpatients
urgedtourinateevery1-2hourstoensureurinary
outputofatleast200mleverytwohoursandto
maintainappropriatefluidbalance.Patientsshouldbe
weighedb.i.d.duringcyclophosphamideadministration
toaidinmanagingfluidbalance.Mesnashouldbegiven
totalingthesamenumberof milligramsasthe
cyclophosphamidedoseeachday. SeeMT(S)9006for
Mesnadosing.
MT2004-24: AutoPBSCT inLymphoma
195.1.4.3 PriortoinfusionofPBSConday0, patientswillreceive
6hoursof hydrationwithD 51/2NS+20mEqKCL/Lata
rateof150ml/hr. Patientswillbeadministered
acetaminophen650mgpoanddiphenhydramine50mg
po30minutespriortoPBSCinfusion
5.1.4.4 Patientswillbeeligibleforadditionalsupportivecare
studyprotocolsincluding,butnotlimitedto,those
relatedtoprophylaxisandtreatmentofinfection,
mucositis,transfusions,nutritionalsupport,graftfailure,
and/orpost-transplant therapyorimmunereconstitution.
5.1.4.5 Allbloodproductsupportwillbeirradiatedtoprevent
inadvertentblooddonorlymphoidengraftment.
StandardBMTprotocolbloodproductsupport
techniqueswillbeused,includingpackedredcell
transfusionstomaintainhemoglobin>8.0g/dl,platelet
transfusionsupporttomaintainplateletcounts
>10,000/μl. Leukocyte transfusions can be used if 
clinicallyindicated.
5.1.4.6 HIVpositivepatientswillremainonoptimized
antiretroviralmedicationregimen,whichwillusuallybe
HAARTtherapy. AstherearenoIValternatives,
HAARTtherapywillbeheldifpatientisunableto
tolerateoralmedicationsandre-institutedassoonas
thepatientcantolerateoraltherapies.
5.1.4.7 Allpatientswillreceivestandardantimicrobial
prophylaxisperinstitutionalprotocols(SeeInfection
ProphylaxisandTherapyGuidelinesforBMTRecipients
atUMMC)
5.1.4.8 Allpatientswillreceiveantiemeticsupportper
institutionalprotocols(seeAntiemeticGuidelineforBMT
RecipientsatUMMC).
5.2 PostTransplantIrradiation
Patient’swillbeeligibleandshouldreceivepost-transplantirradiationafter
diseasere-stagingatDay+28perAppendixIIIandwhenANC>1500/µL
and Plts are > 100,000/µL.  Persisting nodal masses ≥ 2 cm will be treated 
withadditionallocalizedexternalbeamirradiationwithatargettreatmentof
2000–3600cGygivenas150–200cGy/day5days/week.Sites
suspiciousforneoplasticinvolvementbut<2cmandpotentiallyamenable
toradiationshouldhavebiopsyconfirmationof neoplasticinvolvement
beforetreatment.
MT2004-24: AutoPBSCT inLymphoma
205.3 PostTransplantRituximabTherapy
PatientswithCD20+NHLwillbeeligibleforpost-transplantRituximab
therapyiftheyhaverecoveredfromtransplant.Particularlypatientswith
mantlecelllymphomawithhighriskfeaturespriortotransplant(highMIPI
andpositivepreHCTPETormarrowMRD positive)maybenefitfrom
Rituximabmaintenance.Treatment willbestartedbetweenday+45andday
+90aftertransplantandwillberepeatedatday+180±14days.
5.3.3 IndicationsforRituximabtherapy
5.3.3.1 Hematologic: ANC>1500/µLandPltsare>
100,000/uL
5.3.3.2 Recoveryfromallothertransplanttoxicity
5.3.3.3 Absenceofactiveuncontrolledinfections
5.3.4 Dosing
5.3.4.1 Rituximab375mg/m2onceevery2months..
Rituximabisadministeredon day1infusedover6-8hours.
Infusionshouldstartat50mg/hrandincreaseby50mg/hr every30
minutesastoleratedtoamaximalinfusionrateof400mg/hr.
Premedicationwithacetaminophen650mgandbenadryl50mg
orallyforeachinfusion. Hydrocortisone50mgIVmaybe
administeredif necessaryforinfusionreactions.
6REQUIREDOBSERVATIONS(APPENDIXV)
Inadditiontocompletehistoryandphysicalexaminationwithdetailedrecording
ofinitialsitesandcharacteristicsofdiseaseatdiagnosis,immunophenotyping
(molecularbiologicorcytogeneticstudiesasavailable)aswellasprevious
chemotherapyandradiationandtheclinicalresponsestothistreatment,patients
willundergomulti-organscreeningtoassesstheireligibilityforinitiationintothe
studytreatment protocol. Anattemptshouldbemadetoobtainthescheduled
activityascloseaspossibletothescheduleddate. However,scheduling
difficulties(forproceduresandaroundweekends)maymakethisdifficult.
Thereforethescheduledactivitywillbeobtainedwithin14daysof thatschedule.
MT2004-24: AutoPBSCT inLymphoma
216.1Stagingstudiespriortoenrollmenttodefinetheextentofdiseasewill
includeunilateralbonemarrowaspirationandbonemarrowbiopsy, PET/CT
scansof chest,abdomen,pelvis(andneckifindicated), serum protein
electrophoresis, LDH, β 2-microglobulin.
6.1.3 IfpatienthaspreviousPETnegativedisease , thenPETscanisnot
requiredforeligibilityorfollow-up
6.1.4 Ifpatienthashadnopriorbonemarrowinvolvement ,thenbone
marrowbiopsieswillbeperformedtodetermineeligibility,at
day+100,andthenat1yearunlessotherwiseclinicallyindicated.
6.2PBSCcollectiondata: Foreachdayofleukapheresis,thepbCD34/µLprior
tocollection,thetotalnumberofCD34+cellsharvested,thepatient’sactual
weight,theamountofCD34+cells/kgofactualbodyweightandthevolume
of apheresiswillberecorded. Thepatient’sidealbodyweightwillbe
calculatedandincludedinthedatabase.
6.3Diseasestagingwillbeperformedpriortoenrollmentinstudy;atDay+28,
atDay+100,atDay+180,at1yearandthenat6monthintervalsinthe
secondpost-transplant year.
6.4Alldiagnosticbonemarrowaspirationandbiopsystudies(atstudyentry
andthereafter)shallincludeaunilateralaspirateandbilateralbonemarrow
biopsiesforlightmicroscopicmorphologicstudies;aspiratefor
immunophenotyping(lymphomapanel,CellMarker Lab);aspirateto
MolecularDiagnosticslabforgenerearrangementstudies(if appropriate);
andcytogeneticstudiestoevaluatefordevelopmentofmyelodysplasia.
6.5HIV-positivepatientsshouldhaveHIVdiseaseassessed(HIVviralloadand
CD4count)priortostemcellmobilization,at day+28,day+60,day+100
andthenq3monthsduringthefirstpost-transplant year andthenat6
monthintervalsinthesecondandthirdpost-transplant years,andthen
yearlythereafter. IfthereisevidenceofanincreasingHIVviralload,the
patient’sHIVphysicianwillbeconsulted
6.6Evaluationsforimmunereconstitution
6.6.1 QuantitativeImmunoglobulins(IgG,IgM,IgA)shouldbemeasured
priortomobilizationandpost-transplantat day+100,day+180,
andat1year.
6.6.2 Evaluationof CD4andCD8cellsshouldbemeasuredpriorto
mobilizationandpost-transplantatday+100,day+180,and1
year. ForHIV-positivepatients,CD4andCD8analysiswillbe
performedatday+28andday+60aswell.
MT2004-24: AutoPBSCT inLymphoma
227 ENDPOINTS
7.1PrimaryEndpoints
7.1.1 Thepercentofpatientsachievingcompleteresponse,theduration
ofresponseand,ultimately,progressionfree andoverallsurvival
willbeevaluated.
7.1.2 Safetyandoutcomesofautologoustransplantinthemanagement
oflymphomainHIV-positivepatientswithadequatecontrolof HIV
disease.
7.2SecondaryEndpoints
7.2.1 Prospectivevalidationofthepreviouslypublishedformulausedto
estimatetargetedcollectionof PBSC(Section12.0).
7.2.2 Evaluationof immunereconstitutionpost-transplantinpatientswith
HIVdiseasecomparedtoHIVnegativepatients.
7.2.3 Thetimetohemopoieticrecoveryafter transplantation(firstof three
consecutive days of ANC ≥ 0.5 x 109/L;timetoredcelltransfusion-
independence[notransfusionsfor30days];timetoplatelet
independenceof 20x109/Land50x109/L[notransfusionsfor15
days]).
8 TRANSPLANTRELATEDTOXICITIES ANDCOMPLICATIONS
8.1G-CSF
G-CSF
Common LessCommon Rare
none boneor musclepain
injectionsitereaction
(redness, pain,orswelling)allergicreaction
spleenenlargement orrupture
seriouslungproblems (ARDS)
coughingupblood
8.2SideEffectsOf TheChemotherapyForMobilization
Ifosphamide
Common LessCommon Rare
nausea
vomiting
hair loss
bladder irritationandpainor inflammation wherethe
drugwas injected
lowplateletcountwith
increasedrisk ofbleedingtiredness(fatigue)
confusion
sleepiness
seizures
MT2004-24: AutoPBSCT inLymphoma
23Ifosphamide
Common LessCommon Rare
bleeding,bloodintheurine
frequentorpainfulurination
abnormalkidneyfunction
poor appetite
diarrhea
lowwhitebloodcellcount
withincreasedriskof
infectionagitation
dizziness
constipationhallucinations(seeingor
hearingthings thataren'tthere)
severekidneydamageor
kidneyfailure
allergicreaction
abnormalheartrhythm
deathdue toeffectsonthe
brainor othercauses
Carboplatin
Common LessCommon Rare
lowwhitebloodcellcountwith
increasedrisk ofinfection
lowplateletcountwith
increasedrisk ofbleeding
lowredbloodcellcount
(anemia), whichcan make
youtired,dizzy, oreasilyout
of breath
brittlehair
kidneyfunction canbealtered
at highdoses
fetalabnormalities iftaken
whilepregnantnausea
vomiting
lossofappetite
diarrhea
constipation
taste changes
allergicreaction
sensationofpins andneedles
inhands and/or feetrelatedto
nerveirritation
temporaryor permanent
infertility(inabilitytohave
children)confusion
changes invisionor vision
loss(whichimproves after
drugis stopped)
ringinginearsor hearingloss,
whichmaybepermanent
rash
dehydration
sores inthemouthorthroat
severeallergicreaction*
kidneydamage(maygoaway
whendrugis stopped)
liverproblems
hair lossorthinning,including
faceandbodyhair
dizziness
deathdue toallergicreaction,
infection,orothercauses
Etoposide
Common LessCommon Rare
lowwhitebloodcellcountwith
increasedrisk ofinfection
lowbloodplatelet countwith
increasedrisk ofbleeding
nauseaand/orvomiting
lossofappetite
hair loss,includingfaceand
bodyhairconstipation
diarrhea
feverandchills
lowered redbloodcellcount
(anemia)lowbloodpressurewhiledrug
is beinggiven
sores in mouthandthroat
changes inhowfoodstaste
rash,whichcanbecome
serious
itching
numbnessandtinglingin
hands and/orfeet
allergicreactions (mayinclude
chills,fever,rapidheartrate,
trouble breathing, dizziness)
increasedrisk ofasecond
cancer
MT2004-24: AutoPBSCT inLymphoma
24Rituximab
Common LessCommon Rare
mildallergic reactionwith first
infusion(mayinclude fever,
headache, chills, itching,
hives, nausea,shortnessof
breath)allergicreactionwithsecond
andlater infusions
lowwhitebloodcellcountwith
increasedrisk ofinfection
cough
rash,itching
nausea
vomiting
diarrhea
muscleaches
runnynose
sinusinfectionseriousallergic reaction,with
hives,troublebreathing,
tightnessinthechestorthroat,
heartattack,orshock
seriousskinreaction
kidneydamage
lowplateletcountwith
increasedrisk ofbleeding
blockage or holeinthebowel,
withabdominal(belly) pain
lowredbloodcellcount
(anemia) withtirednessand
weakness
deathdue toallergicreaction,
infection,lungdamage,tumor
lysis syndrome, serious skin
rash,bowelobstruction,liver
failurefromreactivated
hepatitis B,andothercauses
8.3PeripheralBloodStemCellCollections
Riskstotheapheresisprocessincluding:
1)bruisingand/orbleedingwheretheneedlesareinsertedfortheapheresis,
2)reactiontocitrate
3)lossof plateletswiththeofstemcellscollection.
4)lossof blood(upto½pint)if thetubingbreaks–thisisveryrare
8.4SideEffectsOf ThePreparative AgentsForTransplantation
8.4.1 Cyclophosphamide,BCNUandEtoposide
Cyclophosphamide
Common LessCommon Rare
lowwhitebloodcellcountwith
increasedrisk ofinfection
hair lossorthinning,including
faceandbodyhair(usually
growsbackaftertreatment)
nausea
vomiting
lossofappetite
sores in mouthoronlips
bleedingfrom bladder,with
bloodin urineallergicreactionwithsecond
andlater infusions
lowwhitebloodcellcountwith
increasedrisk ofinfection
cough
rash,itching
nausea
vomiting
diarrhea
muscleaches
lowplateletcount(mild) withheartproblems withhigh
doses, withchestpain,
shortnessofbreath,or
swollenfeet
severeallergicreactions
skinrash
scarringofbladder
kidneydamage(renaltubular
necrosis)whichcanleadto
kidneyfailure
heartdamage, with trouble
gettingyour breath,swelling
MT2004-24: AutoPBSCT inLymphoma
25Cyclophosphamide
Common LessCommon Rare
diarrhea
long-term orshort-term
infertility(inabilitytohave
children) in womenandmenincreasedrisk ofbleeding
darkeningof nailbeds
acne
tiredness
infection
fetalchangesifyoubecome
pregnant whiletaking
cyclophosphamideoffeet,rapidweight gain
scarringoflungtissue,with
coughandshortnessof
breath
secondcancer,whichcan
happen yearsaftertakingthis
drug
deathfrom infection,bleeding,
heartfailure, allergicreaction,
orothercauses
BCNU (Carmustine)
Common LessCommon Rare
lowwhitebloodcellcount
withincreasedriskof
infection
lowplateletcountwith
increasedrisk ofbleeding
nausea
vomiting
lossofappetite
diarrhea
headache
painalongveinwhilethe
drugis beinggiven
irritationofveinusedfor
giving thedrug
fetalabnormalities if
pregnancyoccurswhile
takingthisdrugscarringoflungtissue,with
coughandshortnessof
breath,whichcanhappen
yearsaftertreatment
flushingofskin
rednessoftheeyes (just after
infusion)
tiredness(fatigue)
lossorthinningofhair
(includinghair ontheface
andbody)
lowredbloodcellcounts
(anemia) causingtiredness
andother symptomstemporarykidneydamage
hardening ofveinusedfor
injection
liverabnormalities, which
usuallyget betterwhen the
drugis stopped
deathdue tolungdamage or
otherproblems
Etoposide
Common LessCommon Rare
lowwhitebloodcellcountwith
increasedrisk ofinfection
lowbloodplatelet countwith
increasedrisk ofbleeding
nauseaand/orvomiting
lossofappetite
hair loss,includingfaceand
bodyhairconstipation
diarrhea
feverandchills
lowered redbloodcellcount
(anemia)lowbloodpressurewhiledrug
is beinggiven
sores in mouthandthroat
changes inhowfoodstaste
rash,whichcanbecome
serious
itching
numbnessandtinglingin
hands and/orfeet
allergicreactions (mayinclude
chills,fever,rapidheartrate,
trouble breathing, dizziness)
increasedrisk ofasecond
cancer
MT2004-24: AutoPBSCT inLymphoma
268.4.2 BEAM
BCNU (Carmustine)
Common LessCommon Rare
lowwhitebloodcellcount
withincreasedriskof
infection
lowplateletcountwith
increasedrisk ofbleeding
nausea
vomiting
lossofappetite
diarrhea
headache
painalongveinwhilethe
drugis beinggiven
irritationofveinusedfor
giving thedrug
fetalabnormalities if
pregnancyoccurswhile
takingthisdrugscarringoflungtissue,with
cough andshortnessof
breath, whichcanhappen
yearsaftertreatment
flushingof skin
rednessofthe eyes (justafter
infusion)
tiredness (fatigue)
loss orthinningofhair
(includinghair onthefaceand
body)
lowredbloodcellcounts
(anemia) causing tiredness
andothersymptomstemporarykidneydamage
hardeningofveinusedfor
injection
liver abnormalities, which
usuallyget betterwhenthe
drugisstopped
death duetolungdamage or
other problemsTotalBodyIrradiation(TBI)
Common LessCommon Rare
nauseaandvomiting
diarrhea
cataracts
sterility
endocrinopathies
growthfailure
intestinalcramps
mucositisparotitis
interstitialpneumonitis
generalized milderythema
veno-occlusivediseasedysphagia
vertebraldeformities
nephropathy
riskof2ndmalignancyyears
later (whengivenalongwith
chemotherapy)
MT2004-24: AutoPBSCT inLymphoma
27Etoposide
Common LessCommon Rare
lowwhitebloodcellcountwith
increasedrisk ofinfection
lowbloodplatelet countwith
increasedrisk ofbleeding
nauseaand/orvomiting
lossofappetite
hair loss,includingfaceand
bodyhairconstipation
diarrhea
feverandchills
lowered redbloodcellcount
(anemia)lowbloodpressurewhiledrug
is beinggiven
sores in mouthandthroat
changes inhowfoodstaste
rash,whichcanbecome
serious
itching
numbnessandtinglingin
hands and/orfeet
allergicreactions (mayinclude
chills,fever,rapidheartrate,
trouble breathing, dizziness)
increasedrisk ofasecond
cancer
Ara-C
Common LessCommon Rare
lowwhitebloodcellcountwith
increasedrisk ofinfection
lowplateletcountwith
increasedrisk ofbleeding
lowredbloodcellcount
(anemia) withsymptomslike
weakness,tiredness,
shortnessofbreath
nausea
vomiting
stomachpain
tiredness(fatigue)
sores in mouthoronlipsdiarrhea
lossofappetite
rash
hair lossorthinning(may
includeface andbodyhair)
fever
muscleandboneaches
liverdamage
bloodclotsandinflammation
oftheveinwherethedrug
was givenredor swollen eyes
sleepiness
muscleweakness
trouble walking
trouble writing
slurred speech
kidneydamage
fetalchangesthatmayleadto
birthdefects,prematurity,or
seriousillnessinthenewborn
ifyoubecome pregnant while
takingthisdrug
allergicreactionwithitching,
dizziness,troublebreathing,
orswellingoftheface,mouth,
orthroat
deathdue toinfection,
bleeding,or othercauses
Melphalan
Common LessCommon Rare
nausea(at higher doses)
vomiting(at higherdoses)
lowwhitebloodcellcount
withincreasedriskof
infection
lowplateletcountwith
increasedrisk ofbleeding
anemia(lowred blood cell
count)withsymptomslike
tiredness,paleness,orshort-term orlong-term
infertility(inabilityto have
children)
weaknesssevereallergicreaction
lossofappetite
scarring(fibrosis) or
inflammationof lungs
hair loss, includingfaceand
bodyhair
rash
itching
second typeofcancer(may
MT2004-24: AutoPBSCT inLymphoma
28Melphalan
Common LessCommon Rare
trouble catchingbreath happen yearsafter
treatment)
deathfromlungdamageor
other causes
8.5PossibleRisksof AutologousTransplant:
Duringthecellinfusion: nausea,chills
Duringthepost-transplantperiod:
lowbloodcountsincreasingtheriskofinfectionandbleeding
suppressionof theimmunesystem
risksof cancerrecurrence
9ADVERSEEVENTREPORTING
ToxicityandadverseeventswillbeclassifiedaccordingtoNCI'sCommon
TerminologyCriteriaforAdverseEventsV3.0(CTCAE)andreportedonthe
schedulebelow. Acopyof theCTCAEcanbedownloadedfromtheCTEPhome
page
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev
3.pdf).
9.1 Definitions
The following definitions are based on the Code of Federal Regulations
Title21Part 312.32(21CFR312.32(a)).
Adverse Event: Any untoward medical occurrence associated with the
useofadruginhumans,whether ornotconsidereddrugrelated.
Suspected Adverse Reaction: Any adverse event for which there is a
reasonablepossibilitythatthedrugcausedtheadverseevent.
Life-Threatening Adverse Event Or Life-Threatening Suspected
Adverse Reaction: An adverse event or suspected adverse reaction is
considered “life-threatening” if, in the view of either the investigator or
sponsor, its occurrence places the patient or subject at immediate risk of
death.
MT2004-24: AutoPBSCT inLymphoma
29Event AttributionCategories:
CTCAE does not define an AE as necessarily ‘caused by a therapeutic
intervention.’ The clinical investigator must assign attribution for an
adverseevent afternamingandgradingoftheevent.
Attribution Description
Unrelated TheAEisclearlyNOTrelatedtotheintervention
Unlikely TheAEisdoubtfullyrelatedtotheintervention
Possible TheAEmayberelatedtotheintervention
Probable TheAEislikelyrelatedtotheintervention
Definite TheAEisclearlyrelatedtotheintervention
Unanticipated (unexpected) adverse event or unexpected suspected
adverse reaction as defined by the University Of Minnesota IRB are
those that are notalready describedas potential risksin theconsent form,
notlisted in the Investigator’s Brochure or notpart of an underlying
disease.
Expedited (Rapid) Reporting: Certain events may require rapid
notification to entities providing patient safety oversight (e.g. IRB) as
detailedinsection9.2.
9.2 AdverseEventReportingRequirements
The reporting period for this study is from initiation of study treatment
through engraftment or day 42, whichever occurs earlier; however after
this time point, the investigator must report upon knowledge any study
treatmentrelatedeventmeetingtheexpedited reportingcriteriabelow.
The SAE Coordinator will provide the Cancer Center’s Data and Safety
Monitoring Council (DSMC) with the SAE in an appropriate format
dependingontheindividualSAE(asreportedorinasummaryformat).Agency Criteriaforreporting Timeframe FormtoUse Submission
address/fax
numbersCopyAEto :
UofMN
IRBUPIRTSO :anyeventwhichis
unanticipated,involvednewor
increasedrisktosubjects,andwasat
leastpossiblyrelatedtostudy
proceduresthroughengraftmentorday
42,whicheveroccursearlier10Working
DaysUMCCSAE
MMC820MCCSAE
Coordinator
mcc-
saes@umn.edu
OtherProblemsorEvents meeting
thedefinitionofUPIRTSOUPIRTSO
Form
MCCSAE
CoordinatorAnyeventthatcountstowardastudy
stoppingrule(seesection11.2.2)Upon
reportingStudy
stoppingrule
form
MT2004-24: AutoPBSCT inLymphoma
3010 DATAANDSAFETYMONITORING
The study’s Data and Safety Monitoring Plan will be in compliance with the
University of Minnesota Masonic Cancer Center's Data & Safety Monitoring Plan
(DSMP), which can be accessed at
http://www.cancer.umn.edu/exfiles/research/dandsmplan.pdf .
Forthepurposesofdataandsafetymonitoring,thisstudyisclassifiedasmoderate
risk. Thereforethefollowingrequirementswillbefulfilled:
 The PI will complete and submit a quarterly Trial Progress Report to
the Masonic Cancer Center Data and Safety Monitoring Council (DSMC) with the
understanding the Cancer Protocol Review Committee (CPRC) may require more
frequentreporting.
 ThePIwillcomplywithatleasttwiceyearlymonitoringoftheproject by
theMasonicCancerCentermonitoringservices.
 The PI will oversee the submission of all reportable events per the
definition of reportable in section 9.2 to the Masonic Cancer Center’s SAE
CoordinatorandtheUniversityofMinnesotaIRB.
AtthetimeoftheIRBcontinuingreview,thePrincipalInvestigatorwillsubmittothe
CPRCacopyof alldocumentationsubmittedtotheIRBforcontinuingreview.
11EXPERIMENTALDESIGN ANDSTATISTICAL CONSIDERATIONS
11.1 Estimated Accrual
Itisestimatedthatapproximately30patientsperyearwillbeaccruedto
thisstudy. Of these30patients,approximately5peryearareexpectedto
beHIVpositive.
11.2 PrimaryEndpointanalyses
11.2.1Time-to-eventanalysesof progression-freeandoverallsurvival
Progression-free(PFS)andoverallsurvival(OS)willallbe
assessedbytime-to-eventanalyses. Basedontheeventrate
frompriordatacollectedfromthisinstitutiononprotocolMT1995-
27,theanticipatedprecisionof thePFSestimateis±2.5%at1
yearand±3.3%at5years. ForOS,theanticipatedprecisionis
±1.5%at1yearand±3.6%at 5years.
Kaplan-Meierandcumulativeincidenceplotswilldescribethe
distributionof eventtimes.Foreventsexperiencedbygreaterthan
50%ofpatients,medianeventtimesandconfidenceintervalswill
MT2004-24: AutoPBSCT inLymphoma
31bereported.Log-ranktestswillassessdifferencesbetweenHIV
positiveandnegativepatients
11.2.2SafetyofautologousPBSCHSCTinpatientswithHIVdisease
andrelapsedlymphoma
Itisestimatedthatapproximately5HIVpositivepatientsperyear
willbeenrolled. Stoppingruleswillbeimplementedbasedon
numbersofunexpectedadverseeventsinthecohortof HIV
positivepatients. Basedoncurrentavailableliteraturefor
autologousHSCTinHIVpositivepatientswithlymphoma,
morbidityandmortalityaresimilartonon-HIVinfectedpatients
(i.e. ≤ 5%).  Based on this information, the study would be 
reviewedif thefollowingoccur:
2eventsinthefirst2patientsenrolled
3eventsoccurringuptoandincluding15patientsenrolled
4eventsoccurringuptoandincluding22patientsenrolled
5eventsoccurringuptoandincluding30patientsenrolled
Thesestoppingrulescontrolthechanceofstoppingto4.9%if the
eventrateisatanacceptable5%whilegivingan80.7%chanceof
stoppingiftheeventrateis20%. Otherprobabilitiesofstopping
thestudyareincludedinthetablebelow.
EventRate ProbabilityofStoppingAccrual Expectednumberof
subjectsenrolledbefore
stopping
8% 16.5% 28
10% 27.5% 26
15% 57.7% 21
18% 72.9% 18
20% 80.7% 16
25% 93% 13
30% 97.9% 10
11.3 SecondaryEndpointAnalysis
11.3.1Comparisonof theactualCD34+cellscollectedversusthe
collectionestimatedbytheformula(Section12.2):
Theaccuracyof theformula’sestimationof CD34+cellcollection
willbeassessedbyastatisticaldescriptionofthedifference
betweenactualandestimateddailycollectionofCD34+cells.This
differenceistheformula’sdiscrepancy.
MT2004-24: AutoPBSCT inLymphoma
32Arepeatedmeasures(variancecomponents)modelwillbeused
toaccountforthecorrelationof dailydifferencesfromthesame
patient.
Estimatesofthemeandailydifferenceandthestandarddeviation
ofthedailydifferencesbothwithinandbetweenpatientswill
characterizetheformula’sperformance.
Acriterionof acceptablevariationintheformula’sdiscrepancyis
specifiedapriori.Thelower95%confidenceintervalforthe
predicteddiscrepancyshallnotfallbelowzerobymorethan1/3
thepredictedCD34+cellcollectionforCD34+cellcollectionlevels
intherange(0.3, 1.5)x106cells/kg.Forexample,foraformula-
predictedCD34+cellcollectionof0.5x106cells/kg,thelowerend
ofthe95%confidenceintervalaroundthediscrepancyshouldbe
±0.167,indicatinghighconfidencethatactualcollectionwillfall
between0.33and0.67x106cell/kg.
Testswillalsobeperformedtodetermineif themeanand
standarddeviationof theformula’sdiscrepancyvarybypbCD34,
collectionday,diseasestage,typeoflymphoma,andHIVstatus.
11.3.2AssessmentofCD34+cellcollection
CD34+cellcollectiondatawillbedescribedbyitsdistribution,
mean,median,rangeandstandarddeviationbothwithinpatient
andacrossallpatientcohorts.
RegressionanalysisofCD34+cellcollectionwillbeperformedto
estimatepotentialeffectsofcollectionday,pbCD34
measurement,HIVstatusandpatientandlymphoma
characteristicsoncellcounts.
11.3.3ImmunereconstitutionwillbecomparedbetweenHIVnegative
andpositivepatients.
Immunereconstitutionwillbeassessedbythetimefrom
transplant untilmeasuredlevelsreturntothelowerof apatient’s
pre-transplantlevelandaclinicallynormallevel.This
assessmentwillbeperformedforCD4,CD8, andquantitative
immunoglobulins(IgG, IgM,IgA).
Statisticalcomparisonwillbeperformedbyalog-ranktestto
compareKaplan-Meier curvesdescribingtime-to-reconstitution
foreachmeasuredquantity.
11.3.4Descriptivestatisticsforpatientandlymphomacharacterization
MT2004-24: AutoPBSCT inLymphoma
33Patientdemographics,clinicalhistory,andattributesoftheir
lymphomaswillbedescribedstatisticallyusingmeans,medians,
ranges,andstandarddeviationsforquantitativevariablesand
frequenciesforcategoricalvariables.DifferencesbetweenHIV
positiveandnegativepatientswillbeassessedusingt-testsand
chi-squaredtests
11.3.5Time-to-eventanalysesof engraftmentof neutrophilsand
platelets
Engraftmentwillbeassessedbytime-to-eventanalyses.Kaplan-
Meierandcumulativeincidenceplotswilldescribethedistribution
ofeventtimes.Foreventsexperiencedbygreaterthan50%of
patients,medianevent timesandconfidenceintervalswillbe
reported. Log-ranktestswillassessdifferencesbetweenHIV
positiveandnegativepatients.
12 ESTIMATIONOFCELLS
12.1 Hypothesis: Usingasetvolumeof apheresisandtheestimated
collectionefficiency(CE)aswellasthemeasuredpbCD34/µLanddonor
idealbodyweight(IBW)inkilograms,thenumberofpbCD34collectedcan
beaccuratelyestimatedpriortoharvest
12.2 Formulas:
PredictionofCD34+cellscollected:
(Volumeof Apheresis)x(CE)x[(pbCD34/µL)/(IBW)]
VolumeofapheresiswillberecordedbytheDonorCenterforevery
collection
Basedonrecentanalysesof stemcellcollections,theestimated
collectionefficiency(CE)attheUniversityofMinnesotadonorcenteris
60±0.5%
PeripheralBlood(pb)CD34/µL=WBCcountx%CD34
WBCcountisreportedinthecomputerx109/L
%CD34isreportedbytheFlowcytometrylabasthepercentage
ofmononuclearcellsthataredualpositiveforCD45andCD34
Thefactor10correctsforconversionofWBCtocells/µLandthe
%CD34toanabsolutenumber
EXAMPLE: Patient’sWBCisreportedas5.7x109/Landthe
%CD34isreportedas0.25%then
pbCD34/µL=5.7x0.25=1.425/µL
MT2004-24: AutoPBSCT inLymphoma
34Idealbodyweightiscalculatedusing:
50kg+[2.3kgx(heightininches-60)]formen
45.5kg+[2.3kgx(heightininches-60)]forwomen
Adjustedbodyweight=IBW +0.5(ABW -IBW)
13 ADMINISTRATIVE PROCEDURES
13.1 InformedConsent
Afterthepatientisfullyevaluatedandavailableclinicaldataisreviewedbythe
attendingphysician,eligiblepatientsarepresentedwithspecificdetailsofthe
treatmentplan.Therecommendedtherapeuticstepsarediscussedthoroughly
withthepatientandfamily.Therisksoftheprocedureareoutlineincludingthe
primingof PBSCchemotherapyplusG-CSF,theperipheralstemcellcollections,
thepre-transplantchemotherapyand/orradiation;thetransplantationhospital
course;thepotentialneedforlocalradiationtreatmentpost-transplantandthe
needforongoingfollow-upevaluationtomonitorthepatient'spost-transplant
recovery.
Therationaleof thestudyaswellasthehazardsofthesecomponentsof
treatmentisexplainedtothepatientinfullandallquestionsareansweredas
completelyaspossible.Alternativeformsoftherapyarepresented.Afterthis
presentation,informedconsentisobtainedusingformsapprovedbythe
Universityof MinnesotaIRB:HumanSubjectsCommittee.
13.2RecordsRetention
Theinvestigator,throughtheCTOandBMTresearchdatabase, willretainstudy
records,includingsourcedataandallstudycorrespondenceinasecuredfacility
for6yearsfromthedateofthestudyfileclosurewiththeIRB. Inaddition,the
ClinicalTrialsOffice(CTO) willkeepamasterlogofallpatientsparticipatingin
thestudy, withsufficientinformationtoallowretrievalofthemedicalrecordsfor
thatpatient.
14 REFERENCES
1. NebenK,HohausS,GoldschmidtH,EgererG,VosoMT,HoAD,HaasR.
High-dosetherapywithperipheralbloodstemcelltransplantationforpatientswith
relapsedorrefractoryHodgkin'sdisease:long-termoutcomeandprognosticfactors.
AnnHematol.2000;79:547-555
2. PhilipT,GuglielmiC,HagenbeekA,SomersR,VanderLelieH,BronD,
SonneveldP,GisselbrechtC,CahnJY,HarousseauJL.Autologousbonemarrow
transplantationascomparedwithsalvagechemotherapyinrelapsesof chemotherapy-
sensitivenon-Hodgkin'slymphoma.NEnglJMed.1995;333:1540-1545
MT2004-24: AutoPBSCT inLymphoma
353. ChaoN,SchriberJ,GrimesK,LongG,NegrinR,RaimondiC,HorningS,
BrownS,MillerL,BlumeK.Granulocytecolony-stimulatingfactor"mobilized"peripheral
bloodprogenitorcellsaccelerategranulocyteandplateletrecoveryafterhigh-dose
chemotherapy.Blood.1993;81:2031-2035
4. SchmitzN,LinchDC,DregerP,GoldstoneAH,BoogaertsMA,FerrantA,
DemuynckHM,LinkH,ZanderA,BargeA.Randomisedtrialoffilgrastim-mobilised
peripheralbloodprogenitorcelltransplantationversusautologousbone-marrow
transplantationinlymphomapatients.Lancet. 1996;347:353-357
5. BensingerW,AppelbaumF,RowleyS,StorbR,SandersJ,LillebyK,Gooley
T,DemirerT,SchiffmanK,WeaverC,etal.Factorsthatinfluencecollectionand
engraftmentofautologousperipheral-bloodstemcells.JClinOncol.1995;13:2547-
2555
6. ArmitageS,HargreavesR,SamsonD,BrennanM,KanferE,NavarreteC.
CD34countstopredicttheadequatecollectionofperipheralbloodprogenitorcells.
BoneMarrowTransplant.1997;20:587-591
7. BorbollaJ,NajeraA,Lopez-HernandezM,GonzalezM,SillerA,RubioB,
GarcesO,DelgadoJ,ColladosM.CorrelationCoefficientsBetweenSeveral
ParametersandCD34+CellYieldinPeripheralBloodStemCellHarvestingby
Apheresis.JHematotherStemCellRes.2001;10:17-18
8. ChappleP,PrinceH,QuinnM,BertoncelloI,JunejaS,WolfM,Januszewicz
H,BrettellM,GardynJ,SeymourC,VenterD.PeripheralbloodCD34+cellcount
reliablypredictsautograftyield.BoneMarrowTransplant.1998;22:125-130
9. TomblynM,RogersT,AroraM,BarkerJ, BrunsteinC,BurnsLJ,KaufmanD,
McGlaveP,MillerJ,SlungaardA,WeisdorfD.PredictiveFactorsforAdequate
HematopoieticStemCellMobilizationwithHematopoieticGrowthFactorAlonein
PatientswithLymphoma.BiolBloodMarrowTransplant.2005;11:68
10. BenjaminRJ,LinsleyL,FountainD,ChurchillWH,SieffC,CannonME,Uhl
L,GaynesL,AntinJH,WheelerC.PreapheresisperipheralbloodCD34+mononuclear
cellcountsaspredictorsof progenitorcellyield.Transfusion.1997;37:79-85
11. ArmitageS,HargreavesR,SamsonD,BrennanM,KanferE,NavarreteC.
CD34countstopredicttheadequatecollectionofperipheralbloodprogenitorcells.
BoneMarrowTransplant.1997;20:587-591
12. GidronA,DoyleM,GordonL,SinghalS,TallmanM,WilliamsS,WinterJ,
TomblynM,VermaA,MehtaJ.SignificanceofLowPeripheralBloodCD34+Cell
NumbersPriortoLeukapheresis:Shouldthe5/microLThresholdRequiredfor
ApheresisbeChanged?BiolBloodMarrowTransplant.2004;10:15- 16
13. GabarreJ,AzarN,AutranB,KatlamaC,LeblondV.High-dosetherapyand
autologoushaematopoieticstem-celltransplantationforHIV-1-associatedlymphoma.
Lancet.2000;355:1071-1072
14. KrishnanA,ZaiaJ,MolinaA.Stemcelltransplantationandgenetherapyfor
HIV-relatedlymphomas.JHematotherStemCellRes.2002;11:765-775
15. MolinaA,KrishnanAY,NademaneeA,ZabnerR,SniecinskiI,ZaiaJ,
FormanSJ.Highdosetherapyandautologousstemcelltransplantationforhuman
immunodeficiencyvirus-associatednon-Hodgkinlymphomaintheeraofhighlyactive
antiretroviraltherapy.Cancer.2000;89:680-689
MT2004-24: AutoPBSCT inLymphoma
3616. KrishnanA,MolinaA,ZaiaJ,NademaneeA,KogutN,RosenthalJ,WooD,
FormanSJ.AutologousstemcelltransplantationforHIV-associatedlymphoma.Blood.
2001;98:3857-3859
17. ReA,CattaneoC,MichieliM,CasariS,SpinaM,RupoloM,AllioneB,
NosariA,SchiantarelliC,ViganoM,IzziI,FerremiP,LanfranchiA,MazzuccatoM,
CarosiG,TirelliU,RossiG.High-dosetherapyandautologousperipheral-bloodstem-
celltransplantationassalvagetreatmentforHIV-associatedlymphomainpatients
receivinghighlyactiveantiretroviraltherapy.JClinOncol.2003;21:4423-4427
18. RituximabProductLabelapprovedbytheFDA.2004
19. ChesonBD,HorningSJ,CoiffierB,ShippMA,FisherRI,ConnorsJM,Lister
TA,VoseJ,Grillo-LopezA,HagenbeekA,CabanillasF,KlippenstenD,HiddemannW,
CastellinoR,HarrisNL,ArmitageJO,CarterW,HoppeR,CanellosGP.Report of an
internationalworkshoptostandardizeresponsecriteriafornon-Hodgkin'slymphomas.
NCISponsoredInternationalWorkingGroup.JClinOncol.1999;17:1244
MT2004-24: AutoPBSCT inLymphoma
37AppendixI
KarnofskyPerformanceStatus
KARNOFSKYPERFORMANCESTATUSSCALEDEFINITIONSRATING(%)
CRITERIA
Abletocarryonnormalactivityandtowork;
nospecialcareneeded.100Normalnocomplaints;noevidence
ofdisease.
90Abletocarryonnormalactivity;
minorsignsorsymptomsof
disease.
80Normalactivitywitheffort;some
signsorsymptomsofdisease.
Unabletowork;abletoliveathomeand
careformostpersonalneeds;varying
amountofassistanceneeded.70Caresforself;unabletocarryon
normalactivityortodoactivework.
60Requiresoccasionalassistance,
butisabletocarefor mostofhis
personalneeds.
50Requiresconsiderableassistance
andfrequentmedicalcare.
Unabletocareforself;requiresequivalent
ofinstitutionalorhospitalcare;diseasemay
beprogressingrapidly.40Disabled;req uiresspecialcareand
assistance.
30Severelydisabled; hospital
admissionisindicatedalthough
deathnotimminent.
20Verysick;hospitaladmission
necessary;activesupportive
treatmentnecessary.
10Moribund;fatalprocesses
progressingrapidly.
0 Dead
MT2004-24: AutoPBSCT inLymphoma
38AppendixII
ResponseCriteriaforNon-Hodgkin'sLymphoma
ResponseCategoryPhysical
ExaminationLymph
NodesLymph
Node
Masses BoneMarrow
CR Normal Normal Normal Normal
CRu Normal Normal Normal Indeterminate
Normal Normal >75%
decreaseNormalor
indeterminate
PR Normal Normal Normal Positive
 Normal ≥50% 
decrease50%
decrease
Decreasein
liver/spleen50%
decrease50%
decrease
Relapse/progression Enlarging
liver/spleen;new
sitesNewor
increasedNewor
increasedReappearance
1. CR: Completedisappearanceofalldetectableclinicalandradiographicevidenceof
diseaseanddisappearanceof alldisease-relatedsymptomsifpresentbefore
therapy, andnormalizationof biochemicalabnormalities(i.e.LDH)attributable
todisease. Alllymphnodesandnodalmassesmusthaveregressedto
normal size (< 1.5 cm in their greatest transverse diameter for nodes ≥1.5 cm 
beforetherapy). Previouslyinvolvednodesthat were1.1to1.5cmintheir
greatesttransversediameterbeforetreatment musthavedecreasedto<1cm
intheirgreatesttransversediameteraftertreatment. Thespleen,ifconsidered
tobeenlargedbeforetherapyonthebasisofaCTscan,musthaveregressed
insizeandmustnotbepalpableonphysicalexamination.If thebonemarrow
wasinvolvedbylymphomabeforetreatment,theinfiltratemustbeclearedon
repeatbonemarrowaspirateandbiopsy.
2. CRu: IncludespatientswhofulfillthecriteriaforCRbutwiththefollowingfeatures:
Aresiduallymphnodemassgreaterthan1.5cmingreatesttransverse
diameterthathasregressedbymorethan75%.Individualnodesthatwere
previouslyconfluentmusthaveregressedbymorethan75%comparedwith
MT2004-24: AutoPBSCT inLymphoma
39thesizeoftheoriginalmass.Indeterminatebonemarrow(increasednumber
orsizeofaggregateswithoutcytologicorarchitecturalatypia).
3. PR: Atleast50%regressionindiameterofmajornodalmasses. Noincreasein
thesizeoftheother nodes,liver,orspleen. Splenicandhepaticnodulesmust
regressbyatleast50%. Withtheexceptionofsplenicandhepaticnodules,
involvementof otherorgansisconsideredassessableandnotmeasurable
disease. Bonemarrowassessmentisirrelevantfordeterminationof aPR
becauseitisassessableandnotmeasurabledisease;however,if positive,the
celltypeshouldbespecified. Nonewsitesofdisease.
4. StableDisease:
ThisisdefinedaslessthanaPRbutisnotprogressivedisease.
5. ProgressiveDisease:
Atleasta50%increasefromnadirofanypreviouslyidentifiedabnormalnode.
Appearanceof anynewlesionduringorattheendof therapy.
MT2004-24: AutoPBSCT inLymphoma
40AppendixIII
Calculationof AUCforCarboplatindosingusingCalvertformula
CarboplatinDose(mg)=targetAUC(mg/mLxmin)x[GFR(mL/min)+25]
GFR(mL/min)= (wtinkg)x(140–age)/[72xCreatinine]
**forwomen,multiplyresultby0.85
MT2004-24: AutoPBSCT inLymphoma
41AppendixIV
CellCollection,StorageandUse/VascularAccessfor Apheresis
Peripheralbloodstemcellswillbecollectedusingavailableapheresismachines.
CurrentlyattheUniversityHospital,theFenwalCS3000isavailableandwillbeused.A
standardtechnique,usingamodificationof programone,runat1400rpm,willbeused.
Procedureswillbeperformedusingeitherantecubitalveinsor13.5Fr Quinton/Davol
cathetersifantecubitalveinsarenotappropriateforapheresiscollection.Peripheral
bloodmononuclearcellcollectionswillbeperformedonweekendsonlyifclinically
appropriate.
Peripheralbloodcellswillbecombinedwithanequalvolumeof 20%dimethylsulfoxide
(DMSO) in protein containing media for a final concentration of ≤ 300x106nucleated
cellsperkgand10%DMSO.Thecellconcentratewillthenbefrozenatacontrolled
rateinaprogrammablecontrolledratefreezer(1°minutethrough-60°Cand3°minute
through-90°C).Thefrozencellconcentrateswillbestoredinthevaporphaseof liquid
nitrogen.
QualitycontrolincludingcarefulmeasurementofCD34%,absoluteMNCandNCcounts
willbeperformed. Thetotalnumberof CD34cellscollected(notweightbased)aswell
astheCD34/kgactualbodyweightwillbereported.
SeeSection5.2forguidelineforcontinuationofpoorcollections.
MT2004-24: AutoPBSCT inLymphoma
42AppendixV
DosingofG-CSFandVolumeof Apheresisbasedonpatientactualbodyweight
BODYWEIGHT DOSEOFG-CSF VOLUMEOFAPHERESIS
<40Kg 300mcg 6L
40–45kg 300mcg 6L
45–50 kg 480mcg 8L
51–55kg 480mcg 8L
56–60kg 600mcg 10L
61–65kg 600mcg 10L
66–70kg 600mcg 10L
71–75kg 780mcg 12L
76–80kg 780mcg 12L
81–85kg 900mcg 12L
86–90kg 900mcg 12L
91–95kg 900mcg 12L
>95kg 1260mcg 15L
MT2004-24: AutoPBSCT inLymphoma
29AppendixVI
RequiredObservations
within30
daysof
enrollmentStartof
mobilizationDaily
during
apheresisPriorto
Admitfor
transplantday
+28day
+60day
+100day
+1801
yr1
8
m
o2y
r
MedicalHistory x x x
PhysicialExam x x x x x x x x x x x
Weight/Height x x x x
Performance
statusx x x x x x x x x x
Adverse
Event/toxicity
notationx x x x x x x x x x x
Comprehensive
chemistrypanelx x x x x x x x x
HepaticPanel x x x x x x x x x
CBCwithdiff x x x x x x x x x x x
*SPEP x x x
LDH x x x x x x x
*ß2-
microglobulinxx x
HIVviralload2x x x x x x x x x
ViralHepatitis
serologiesx
quantitative
Immunoglobulinxx x x
pbCD4+x x2x2x x x2x x2
pbCD8+x x2x2x x x2x x2
%CD34cells
priorto
collectionx x
Bilateralbm
biopsy
unilateral
aspiratex x1x x x
CTscan–
chest,
abdomen,
pelvis(neckif
indicated)x x x x x x x
PETscan x x x
Flowcytometry x x1x x x
BM
Cytogeneticsx x x x
CD34+cells
harvested
(totalnumber)x
Volumeof
apheresisx
1Day28bonemarrowbiopsyandflowcytometrytobe performedONLYifpriorhistoryofmarrow
involvement
2OnlyforHIV-positive patients
3Ifpatientiseligibleforpost-transplant radiationtherapyandhas priorPET-positivedisease.
*forCLL +lowgradelymphomas only
MT2004-24: AutoPBSCT inLymphoma
30Anattemptshouldbemadetoobtainthescheduledactivityascloseaspossible
tothescheduleddate. However,schedulingdifficulties(forproceduresand
aroundweekends)maymakethisdifficult. Therefore,thescheduledactivitywill
beobtainedwithin14daysof thatschedule(30daysfordatesafterday+100).